Pre-made Cibisatamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-CEACAM5/CD66e;CD3E therapeutic antibody, Anti-CEA;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-CEACAM5/CD66e;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover, Anti-CEA;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cibisatamab, an investigational drug, is a bispecific antibody, which means it binds to two different proteins: one called CEACAM5 on the surface of some colorectal cancer cells and another on T cells called CD3.
| Products Name (INN Index) | Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody |
|---|---|
| INN Name | Cibisatamab |
| Target | CEACAM5&CD3E,CD3E |
| Format | Bispecific mAb with Domain Crossover |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Roche |
| Conditions Approved | NA |
| Conditions Active | Non-small cell lung cancer,Colorectal cancer |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CEACAM5,CD3E |
| Package |
